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For patients with squamous cell carcinoma of the vulva, surgical
therapy comprises vulvectomy or wide local excision and bilateral
or unilateral lymphadenectomy. Better insight into carcinogenesis
and progression of the disease is needed to provide arguments for
a more tailored treatment of the individual patient. As p53 and
mdm2 are genes known to be involved in development of other
tumours, we investigated the presence of p53 and mdm2 in
carcinogenesis of squamous cell carcinoma of the vulva and
whether immunohistochemical detection of the gene products is
of clinical relevance.
p53, a tumour suppressor gene located on the short arm of chro-
mosome 17, plays an important role in the regulation of the cell
cycle (Hartwell and Kasten, 1994; Prokocimer and Rotter, 1994).
Genetic alteration of this gene is associated with prognostic
relevance in several tumours (Charpin et al, 1995; Esrig et al,
1994; Florenes et al, 1994; Shurbaji et al, 1995; Sun et al, 1992;
Vogt et al, 1997), including vulvar carcinomas (Kohlberger et al,
1995; Milde-Langosch et al, 1995). It has been shown that cells
defective for the p53 gene continue to enter the S phase after
irradiation with an increased chance for aberrant DNA to be
duplicated. Loss of the G1–S checkpoint in cell division can lead
to genomic instability and potential development of malignancy.
p53 is presumed to prevent genomic instability, upon exposure to
DNA damaging agents (Lane, 1992).
Mutation of the p53 gene gives rise to a p53 oncoprotein that is
more stable than the wild-type (wt) protein and therefore can
accumulate in the cell. Detection of the mutant p53 protein is
possible by immunohistochemistry (Lassam et al, 1993; Shurbaji
et al, 1995). However, non-sense mutations, or mutations not
encoded on exon 5 to exon 8 of the p53 gene, are not detectable on
protein level (Bosari and Viale, 1995; Bosari et al, 1995).
The  mdm2 gene, localized on chromosome 12q13–14, is
presumed to be a negative regulator of p53. This is based on the
finding that mdm2 gene product, a 95 kDa protein, can form
complexes with the p53 protein, and overexpression of mdm2
inhibits the functioning of p53 (Momand et al, 1992). Moreover,
amplification of mdm2 is shown to be involved in tumorigenesis of
human sarcomas (Oliner et al, 1992). Furthermore it is demon-
strated that expression of the mdm2 gene is regulated by transient
induction of wt p53 activity (Barak et al, 1993). Wu et al (1993)
demonstrated that the induction of mdm2 by p53 occurs at the
level of transcription.
The aims of this study of squamous cell carcinoma of the vulva
were: to establish the pattern of expression of p53 and mdm2
protein in primary tumours, vulvar intraepithelial neoplasia (VIN),
epithelia adjacent to the tumour (EAT) and in lymph node metas-
tases (LNM); to determine whether p53 and mdm2 are involved
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in metastasis; and to address the possible relationship between
p53an d mdm2expression.
MATERIALS AND METHODS
Patients
Data were obtained from samples of 141 patients with primary
invasive squamous cell carcinoma of the vulva who were treated
with vulvectomy ( 115) or wide local excision (26) and bilateral
inguinofemoral lymphadenectom y. None of these patients
received preoperative therap y. All patients were su r gically treated
between 1982 and 1992 at the Department of Gynecological
Oncolog y, University Hospital Groningen. The tumours did not
extend to the urethra, vagina or anus and were not fixed to the
pelvis (T1 and T2 tumours). Depth of invasion was more than
1mm. The age range of the patients was 29–94 years with a
median value of 71 years.  Twenty-eight per cent of the patients
(39/141) had inguinofemoral LNM. Pre-existent E AT of 90
patients and VIN lesion adjacent to the tumour of 14 patients were
also studied. E AT with morphologic abnormalities consistent with
known disease entities, such as lichen sclerosis and hyperplasia,
were not included. This series consisted of 64 patients with di ffer-
entiation grade 1, 63 with grade 2 and 14 with grade 3.
Methods
mdm2 and p53 immunostaining
We used formalin-fixed, para ffin-embedded tissue of vulvar
tumours. Sections of  4mm were mounted on APES-coated slides
(amino-propyl-ethoxy-silan; SIGMA), depara ffinized, rehydrated
to 96% alcohol and air dried. For antigen retrieval we used an
autoclave (Emanuels et al, 1994) in which slides were heated three
times  5min at  115°C in blocking reagent (Boehringer Mannheim)
[2% block + 0.2% sodium dodecyl sulphate (SDS) in maleic acid,
pH = 6.0]. After antigen retrieval, one series of slides was incu-
bated with Bp53–12 (80 0  ´diluted), which is a monoclonal anti-
body recognizing wt and mutant-type p53 protein (BioGenex, San
Ramon, CA, USA) and another series of slides was incubated with
mdm2 Ab-1 (100 ´diluted), which is a mouse monoclonal against
human mdm2 protein (Oncogene Science, Uniondale, N Y, USA).
Two-step immunostaining was performed according to the manu-
facture r ’ s procedure of the Biogenex kit, containing anti-mouse
biotin and conjugated streptavidin. BCIP-NBT (bromochloro-
indolyl-phosphate 4-nitroblue-tetrazolium chloride; Boehringer
Mannheim) was used as substrate. Sections were counterstained
with haematoxylin and mounted with mounting medium. As
negative control, IgG2a was used instead of p53, IgG2b instead of
mdm2. As a positive control multi-tissue block sections were used
composed of 24 di fferent vulvar carcinomas (control for p53) and
one normal skin (control for mdm2). p53 and mdm2 were semi-
quantitatively scored. The scoring categories were: negative (1),
weakly positive (2), moderately to markedly positive (3) and
markedly positive (4). Scores 1 and 2 were grouped together and
considered non-expression, and scores 3 and 4 were grouped
together and considered expression.
Statistical analysis
Pearso n c2 test was used to compare two categorical variables.
Statistical analysis was performed with computer software of the
statistical program SYS TAT.
RESULTS
The group of 141 primary vulvar carcinomas was divided in  118
la r ge primary tumours (invasion dept h  ³3mm) and 23 small
primary tumours (invasion depth <  3mm) (Chu et al, 1982). Of the
141 primary tumours, the corresponding 39 LNM, 90 cases of pre-
existent E AT and 14 cases of VIN lesions adjacent to the tumour
were investigated.
Table 1 represents the scoring categories based on a combina-
tion of staining intensity and pattern. Staining intensity of the
p53-positive cells varied between the di fferent cases, ranging from
weakly to moderately to markedly positive. Staining pattern was
defined as absent, patchy and di ffuse. Heterogeneous staining
was seen in category 3. Overexpression (score 4) of p53 (Figure 1)
was seen in 56% of the LNM, 39% of the la r ge tumours, 39% of
the small tumours and 21% of the VIN. The group of E AT was
p53-negative.
Table 2 represents the distribution of p53 protein expression in
LNM, la r ge tumours, small tumours, VIN lesions and E AT. p53
was seen in undi fferentiated non-keratinizing cells. In all cases,
p53 staining was restricted to dysplastic or tumour cells.
Figure 2 shows the distribution of p53 in the groups studied. An
increase in p53 staining was seen from the group of VIN to the
group of metastases. Marked p53 staining was predominantly seen
in LNM, la r ge and small tumours, and less frequently in the group
of VIN lesions. No p53-positive cases were found in the group of
EAT.
In the groups investigated no significant relation was found
between p53 expression and the absence or presence of LNM.
Neither was there a significant relation with depth of invasion,
differentiation grade, age and greatest diamete r . A total of 35%
(19/55) of the markedly positive primary tumours were metasta-
sized. Expression of p53 in the 39 metastases was highly corre-
lated with expression of p53 in the corresponding primary tumours
Table 1Categories of p53/mdm2 scoring
Score Staining intensity Staining pattern
1  Negative  Absent
2  W eak  Patchy
3  Moderate and marked  Patchy
4  Marked  Diffuse
Table 2Number and percentage of p53 expression in the group of
metastases, large vulvar tumours, small vulvar tumours, VIN and E AT
p53 1 2 3 4 Total
Metastases  0  14  3  22  39
0%  36%  8%  56%  100%
Large tumours  39  20  13  46  1 18
33%  17%  1 1%  39%  100%
Small tumours  5  4  5  9  23
22%  17%  22%  39%  100%
VIN  9  2  –  3  14
65%  14%  –  21%  100%
EAT 90  –  –  –  90
100%  –  –  –  100%
VIN = vulvar intraepithelial neoplasia adjacent to tumour; E AT = epithelial
adjacent to the tumou r.40 AG Emanuels et al
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(Pearson  c2;  P = 0.001). Of the 16 markedly p53-positive
metastatic primary tumours, 15 corresponding LNM were also
markedly positive and one was weakly positive. No p53-negative
LNM were found.
In this study, mdm2 staining pattern was comparable to that of
p53 and the same scoring system was used (Table 1). mdm2-
positive cells were localized in the basal layer of EAT and
diffusely throughout VIN lesions and tumours, except for keratin
pearls. In the group of metastases only weak staining was seen
(Figure 3). In general, expression of mdm2 protein was seen less
frequently (20/141) compared to p53 staining (63/141). mdm2
expression tended to decline from EAT to VIN to primary tumours
(Figure 4).
Table 3 shows the distribution of expression of mdm2 in the
groups of LNM, large tumours, small tumours, VIN lesions and
EAT. The highest percentage of mdm2-positive cases were found
in the group of VIN lesions (36%) and EAT (25%), declining in the
group of small tumours (22%) and large tumours (12%). Four
diffuse markedly positive cases were found in the group of large
tumours (which were the only four diffuse markedly positive cases
found in the total group of primary tumours). The number of
mdm2-positive cases in the primary tumours was too low to
establish a statistically significant relation between expression of
mdm2 and other tumour parameters.
In EAT expression, p53 was absent whereas mdm2 was present
and the opposite was seen in the group of metastases, showing
only slight expression of mdm2 and distinct expression of p53.
Co-expression of p53 and mdm2 was found in 6.5% (moderate to
marked staining) and in 7% (weak staining) of the primary
tumours. Inverse expression was found in 53% of the primary
tumours. Within the groups investigated, no significant relation
was found between expression of p53 and mdm2.
DISCUSSION
To individualize surgical therapy for low-risk patients with vulvar
carcinoma, additional parameters to predict LNM are needed. We
investigated expression of p53 and mdm2 protein in relation to
LNM and clincopathological parameters, in a series of 141 T1/T2
squamous cell carcinomas of the vulva, to assess clinical rele-
vance. We were also interested in the distribution and staining
pattern of both gene products and a possible relationship between
p53 and mdm2 and their involvement in carcinogenesis of
squamous cell carcinoma of the vulva.
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Figure 1 Overexpression of p53 in the primary tumour (A and B), in VIN (C and D) (E is an overview of C) and in a LNM (F)Squamous cell carcinoma of the vulva 41
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Previous studies have shown that enhanced expression of p53 is
related to mutation in the p53 gene (Bosari et al, 1995; Esrig et al,
1993; Przygodzki et al, 1996), but this is contradicted by others
(Kennedy et al, 1994; Marchetti et al, 1995). In our study we
detected overexpression of p53 protein and found a higher
percentage of strongly positive tumours in the malignant versus
the premalignant group (Figure 2). Whether overexpression of p53
in this study reflects a mutation or not, our data indicate that
enhanced p53 staining is related to progression from the precursor
lesion to the ultimate development of metastases.
In our study of vulvar tumours, immunohistochemical detection
of p53 overexpression did not contribute to the prediction of LNM.
Neither have we found a relation between p53 and clinicopatho-
logical parameters age, depth of invasion and differentiation
grade. In their study of vulvar carcinomas, Kagie et al (1997) did
not find a relationship between p53 overexpression and disease-
free survival. Kohlberger et al (1995) have reported a relationship
between p53 overexpression and survival in vulvar carcinomas,
based on a group of 25 vulvar carcinomas. In the study by Milde-
Langosch et al, (1995) on vulvar cancer, loss of p53 function was
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Figure 2 Distribution of p53 expression in the groups of EAT, VIN, small
tumours, large tumours and LNM
 
 
 
Figure 3 mdm2 staining in EAT (A), in VIN (B) and in the primary
tumour (C)
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Figure 4 Distribution of mdm2 expression in the groups of EAT, VIN, small
tumours, large tumours and LNM
Table 3 Number and percentage of mdm2 expression in the group of
metastases, large tumours, small tumours, VIN and EAT
mdm2 1 2 3 4 Total
Metastasis 32 5 0 0 37
86% 14% 0% 0% 100%
Large tumours 47 56 11 4 118
40% 48% 9% 3% 100%
Small tumours 13 5 5 0 23
56% 22% 22% 0% 100%
VIN 2 7 5 – 14
14% 50% 36% – 100%
EAT 29 39 16 6 90
32% 43% 18% 7% 100%
VIN = vulvar intraepithelial neoplasia adjacent to tumour; EAT = epithelial
adjacent to the tumour.42 AG Emanuels et al
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associated with a high risk of progression and an unfavourable
prognosis. In the literature the prognostic value of p53 seems to be
controversial, because in some studies p53 is considered pro-
gnostic relevant (Charpin et al, 1995; Esrig et al, 1994; Florenes
et al, 1994; Shurbaji et al, 1995; Sun et al, 1992; Vogt et al, 1997),
whereas in other studies it is not (Bosari et al, 1995; King et al,
1996; Ofner et al, 1995; Xerri et al, 1994; Younes et al, 1995). It
may be that the prognostic value of p53 depends on whether muta-
tion of p53 occurs during carcinogenesis, progression or metas-
tasis of the tumour. Moreover, based on our finding that only 35%
of the enhanced p53-positive cases were metastasized it seems that
additional oncogenic events are necessary for the development of
LNM in vulvar carcinomas.
We divided the group of primary tumours in large (invasion
depth > 3 mm) and small (invasion depth ≤ 3 mm) tumours (Chu
et al, 1982), to see whether the occurrence of aberrant expression
of p53 is relatively higher in large tumours than in small tumours.
No difference was found between the groups of small and large
tumours with respect of expression of p53, indicating that once a
tumour has been developed, aberrant expression of p53 can occur
regardless of the depth of invasion of the tumour.
p53 overexpression can occur early or late in carcinogenesis,
depending on the tumour type (Charpin et al, 1995; Conlter et al,
1995; Kennedy et al, 1994; Lassam et al, 1993). Overexpression of
p53 in our series of vulvar carcinomas appears to occur predomi-
nantly in LNM and primary tumours, and to a much lesser extent
in VIN lesions, and p53 expression is absent in morphologic
normal EAT. This may indicate that overexpression of p53 is a late
event in the development of squamous cell carcinoma of the vulva,
playing a role in tumour progression. Heterogeneity in p53
staining intensity within a tumour was found in 13% of the
primary tumours. It is suggested by Esrig et al (1993) that this
seems to be related to the site of the mutation of the p53 gene or a
combination of wt and mutant-type expressed p53. Weak staining
could represent overexpression of wt p53. LNM and the corre-
sponding primary tumours show similar patterns of p53 expres-
sion, strongly indicating that in metastasized cells the same
aberrant p53 is expressed as in the primary tumour. This was also
reported by Florenes et al (1994), who found in four out of five
p53-positive primary tumours, the same degree of positive
immunostaining in the corresponding metastases. Overexpression
of p53 protein seems to favour survival of metastatic tumour cells.
The reported incidence of mdm2 gene amplification is 10–36%
in non-epithelial tumours, whereas reports regarding epithelial
tumours showed no evidence of aberrant mdm2 gene copy number
(McCann et al, 1995). In the group of primary tumours we found
14% (20/141) mdm2-enhanced positive cases of which only 4/141
were diffuse markedly positive. Our data show that enhanced
expression of mdm2 is a rare event in vulvar carcinomas, which is
also found in other studies of epithelial tumours (Kessis et al,
1993; Marchetti et al, 1995; Quesnel et al, 1994).
No relationship was found between the expression of mdm2
protein and LNM. Whether immunohistochemical detection of
mdm2 expression in this study represents amplification of the gene
is open to discussion. We found no mdm2 staining in LNM and
rarely in the primary tumour in contrast to EAT and VIN. This is in
accordance to the study of Dazard et al (1997), who found that
mdm2 is expressed in normal skin, with lower levels of expression
in squamous cell carcinoma. It seems likely that the presence of
mdm2 staining in the EAT represents normal expression of the
protein. Though mdm2 amplification is rarely seen in epithelial
tumours, it would be interesting to perform genomic analysis
on the four primary tumours and the six EATs showing strong
expression of mdm2.
In recent models regarding interaction of tumour suppressor
genes and proto-oncogenes, mdm2 is designated as a regulator of
the p53 gene and the mdm2 feedback mechanism is activated by
wild-type p53 (Barak et al, 1993). In this regard it would be
expected that overexpression of mutant p53 goes together with
low, or no, expression of mdm2. Within the group of primary
tumours, we found 13% co-expression of p53 and mdm2, and 53%
inverse expression, but a relationship could not be statistically
established. However, we found an increasing percentage of
p53-positive cases in the range of EAT, VIN, primary tumours and
metastases. Exactly the opposite is found for mdm2 expression,
which shows a decreasing percentage of mdm2-positive cases in
the same range. These data suggest that aberrant p53 does not
activate mdm2 expression.
We investigated VIN lesions and pre-existent EAT hypothe-
sizing that these non-malignant cells are not as much dysregulated
as the tumour cells and that detection of p53 and mdm2 protein in
these cells could be used as a possible marker of dysregulation of
these genes in the tumour cells. No such relationship was found.
We conclude from this study that, in squamous cell carcinoma
of the vulva, overexpression of p53 protein is a late event and that
overexpression of p53, even though not genotypically confirmed,
reflects abnormality. Strong expression of mdm2 is rarely seen in
vulvar tumours, indicating that, in squamous cell carcinoma of the
vulva, aberrant p53 cannot induce mdm2. Expression of p53 or
mdm2 cannot be used to predict lymph node metastases.
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